Cancer Biomarker Market: By Biomarker Type (Protein Biomarker, Genetic Biomarker, Others), By Cancer Type (Breast Cancer , Lung Cancer, Prostate Cancer, Non-Hodgkin’s Lymphoma, Bladder Cancer, Kidney Cancer, Liver Cancer, Others), By Profiling Technology (OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, Bioinformatics, Others), By Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Others), and Geography

 

The global cancer biomarkers market size valued at USD 15.06 billion in 2021 and expected to reach USD 31.53 billion by 2028 witnessing a CAGR rate of 11.5% during the forecast period 2022-2028. For instance, according to WHO 2018 data, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, rise in R&D for the development of newer biomarkers, raise in funding from public and private sectors, increase in adoption of cancer biomarkers for drug discovery and development, and surge in demand for early stage disease diagnosis are expected to propel the market over the forecast years. However, stringent regulations for the product approval, high cost for the R&D, and lack of favorable reimbursement guidelines are hamper the growth of market over the forecast years. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global cancer biomarker market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global cancer biomarker market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).